Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Artelo Biosciences Inc (ARTL)

$1.43 -0.03 (-2.05%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	3.38M
Revenue (ttm)	0.00
Net Income (ttm)	-12.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	436,915
Avg Vol	3,989,986
Day's Range	N/A - N/A
Shares Out	2.33M
Stochastic %K	36%
Beta	-0.13
Analysts	Hold
Price Target	$18.00

Company Profile

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 925 7049

Website: artelobio.com

Address:

505 Lomas Santa Fe, Suite 160, Solana Beach, United States

Adubstradesmini Jun. 4 at 2:43 PM

$ARTL Coming soon 7$+

0 · Reply

Adubstradesmini Jun. 4 at 2:43 PM

$ARTL

0 · Reply

Adubstradesmini Jun. 4 at 2:42 PM

$ARTL

0 · Reply

Adubstradesmini Jun. 4 at 2:42 PM

$ARTL

0 · Reply

ya33 Jun. 4 at 2:23 PM

$ARTL

0 · Reply

johanroskam61 Jun. 4 at 2:08 PM

0 · Reply

supplySHOCK Jun. 4 at 10:44 AM

$ACCL $ZNB $ARTL $HUIZ office

0 · Reply

rttr88 Jun. 3 at 7:53 PM

$ARTL going back in for shares. Target is $12-14. Last squeeze went above $19.

1 · Reply

ya33 Jun. 3 at 4:48 PM

$ARTL

0 · Reply

elronjr Jun. 2 at 8:04 PM

$ARTL is this a good company to invest in for the next 6-12 months?

1 · Reply

Artelo Biosciences Proxy statement: Proxy filing

May 20, 2026, 7:00 AM EDT - 15 days ago

Artelo Biosciences Slides: Corporate presentation

May 14, 2026, 4:05 PM EDT - 21 days ago

Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results

Artelo Biosciences Registration statement: Registration filing

May 14, 2026, 8:00 AM EDT - 21 days ago

Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development

2026-04-20T12:15:49.000Z - 6 weeks ago

Artelo Biosciences announces publication of article on ART26.12

Apr 20, 2026, 7:50 AM EDT - 6 weeks ago

Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile

Apr 15, 2026, 7:00 AM EDT - 7 weeks ago

Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength

Artelo Biosciences files to sell 4.27M shares of common stock for holders

2026-03-24T21:35:16.000Z - 2 months ago

Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results

Artelo Biosciences Earnings release: Q4 2025

Feb 24, 2026, 7:00 AM EST - 3 months ago

Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate

Artelo Biosciences Proxy statement: Proxy filing

Dec 11, 2025, 7:00 AM EST - 6 months ago

Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit

Artelo Biosciences Announces Closing of $2.0 Million Public Offering

Oct 1, 2025, 4:05 PM EDT - 8 months ago

Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference

Artelo Biosciences Announces Closing of $3.0 Million Public Offering

Sep 5, 2025, 4:05 PM EDT - 9 months ago

Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

Aug 25, 2025, 7:55 AM EDT - 10 months ago

Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 8:00 AM EDT - 10 months ago

Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13

Aug 7, 2025, 8:00 AM EDT - 10 months ago

Artelo Biosciences Proxy statement: Proxy Filing

Aug 4, 2025, 7:30 AM EDT - 10 months ago

Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset

Aug 1, 2025, 7:45 AM EDT - 10 months ago

Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression

Jul 28, 2025, 8:00 AM EDT - 11 months ago

Artelo Biosciences Proxy statement: Proxy Filing

Jul 11, 2025, 8:00 AM EDT - 11 months ago

Artelo Biosciences Registration statement: Registration Filing

Jul 9, 2025, 7:50 AM EDT - 11 months ago

Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium

Jul 7, 2025, 7:45 AM EDT - 11 months ago

Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model

Jun 30, 2025, 7:45 AM EDT - 1 year ago

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Jun 26, 2025, 8:00 AM EDT - 1 year ago

Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing

Jun 5, 2025, 9:00 AM EDT - 1 year ago

Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

Jun 2, 2025, 9:00 AM EDT - 1 year ago

New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression

Artelo Biosciences Earnings release: Q1 2025

May 13, 2025, 9:30 AM EDT - 1 year ago

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis

Mar 31, 2025, 8:30 AM EDT - 1 year ago

Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025

Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results

Mar 3, 2025, 8:00 AM EST - 1 year ago

Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland

Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12

Jan 13, 2025, 9:00 AM EST - 1 year ago

Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium

Artelo Biosciences Earnings release: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's “Preclinical Screening Platform for Pain” Program

Artelo Biosciences Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Oct 16, 2024, 4:00 PM EDT - 1 year ago

0 · Reply

Adubstradesmini Jun. 4 at 2:43 PM

$ARTL

0 · Reply

Adubstradesmini Jun. 4 at 2:42 PM

$ARTL

0 · Reply

Adubstradesmini Jun. 4 at 2:42 PM

$ARTL

0 · Reply

ya33 Jun. 4 at 2:23 PM

$ARTL

0 · Reply

johanroskam61 Jun. 4 at 2:08 PM

0 · Reply

supplySHOCK Jun. 4 at 10:44 AM

$ACCL $ZNB $ARTL $HUIZ office

0 · Reply

rttr88 Jun. 3 at 7:53 PM

$ARTL going back in for shares. Target is $12-14. Last squeeze went above $19.

1 · Reply

ya33 Jun. 3 at 4:48 PM

$ARTL

0 · Reply

elronjr Jun. 2 at 8:04 PM

$ARTL is this a good company to invest in for the next 6-12 months?

1 · Reply

Adubstradesmini Jun. 2 at 7:21 PM

$ARTL time is coming for 7$

1 · Reply

ya33 Jun. 1 at 8:19 PM

$ARTL

0 · Reply

Adubstradesmini Jun. 1 at 6:20 PM

$ARTL $SLV

0 · Reply

Adubstradesmini May. 31 at 4:25 PM

$ARTL you already this is going to blow soon

0 · Reply

Adubstradesmini May. 31 at 4:24 PM

$ARTL $MWC

0 · Reply

Tahadicaprio May. 31 at 4:21 PM

$ARTL $MWC Time to but these two

0 · Reply

Adubstradesmini May. 30 at 5:00 AM

$SLV $ARTL While everyone’s running and hiding their money those are the best times to buy this

0 · Reply

Adubstradesmini May. 29 at 7:16 PM

$ARTL day by day this will run

0 · Reply

alert716 May. 29 at 1:42 AM

$MASK amazing day over 140% , follow for free alerts 🤑🤑🤑 $ARTL $WGRX $PRFX $CDT

0 · Reply

NYSE_TRADERS May. 28 at 6:55 PM

$ARTL the dumping start again as usual . Garbage !

0 · Reply

NYSE_TRADERS May. 28 at 6:52 PM

$ARTL The only reason for this garbage to go up today is because the short is forbiden for today

0 · Reply

NYSE_TRADERS May. 28 at 6:48 PM

$ARTL Beware ! This is massive fraud !

0 · Reply

1.0.0